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Aims: Ischemic acute kidney injury (iAKI) in experimental diabetes mellitus (DM) is associated with a rapid
kidney dysfunction more than in non-diabetic rats. We hypothesize that this vulnerability is due to excessive
endothelin-1 (ET-1) expression along with dysregulation of nitric oxide synthase (NOS) isoforms. The aim of
the present study was to assess the impact of ischemia on renal function in diabetic rats as compared with
non-diabetic rats, and to investigate the involvement of ET-1 and NO systems in the susceptibility of diabetic
kidney to ischemic damage.
Main methods: DM was induced by Streptozotocin. iAKI was induced by clamping of left renal artery for
30 min. Right intact kidney served as control. 48 h following ischemia, clearance protocols were applied to
assess glomerular ﬁltration rate (GFR), urinary ﬂow (V) and sodium excretion (UNaV) in both kidneys. The
renal effects of ABT-627, ETA antagonist; A192621.1, ETB antagonist; L-NAME, NOS non-selective inhibitor;
1400 W, inducible NOS (iNOS) inhibitor; and NPLA, neuronal NOS (nNOS) inhibitor, were assessed following
ischemic renal injury in diabetic rats.
Key ﬁndings: Induction of iAKI in diabetic and non-diabetic rats caused signiﬁcant reductions in GFR, V, and
UNaV, which were greater in diabetic than non-diabetic rats. While, treatment with ABT-627 decreased V
and UNaV, and increased GFR, A192621.1 decreased all these parameters. L-NAME, 1400 W, and NPLA im-
proved GFR in the ischemic diabetic kidney.
Signiﬁcance: Excessive vasoconstrictive effects of ET-1 via ETA and upregulation of iNOS, are partly responsi-
ble for the impaired recovery of renal function following ischemia in diabetic rats.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Endothelin-1 (ET-1) is produced by most renal cell types, including
glomerular endothelial cells (ECs), mesangial cells, and epithelial cells.
The highest concentrations of ET-1 are detected in the inner renal me-
dulla (Kitamura et al, 1989; Markewitz and Kohan, 1995;Abassi et al.,
2001; Kalani, 2008; Kon and Badr, 1991; Naicker and Bhoola, 2001).
ET-1 affects three aspects of renal function: 1) hemodynamics of the kid-
ney, 2) tubular handling of electrolytes and water, and 3) proliferation
and mitogenesis of certain renal cell types such as mesangium and vas-
cular smooth muscle (Kohan, 1997; Abassi et al., 2001). These actions
are mediated by two receptor subtypes, ETA and ETB. ETA receptor isBiophysics, Faculty of Medicine,
+972 4 8295267.
-NC-ND license.localized in various nephron segments including glomerulus, vasa
recta bundle, and arcuate artery (Terada et al, 1992). In contrast, ETB re-
ceptors are abundantly expressed in glomerular endothelial cells, vasa
recta bundles, epithelial cells of thin segments of Henle's loop and col-
lecting duct (Terada et al, 1992; Naicker and Bhoola, 2001). Systemic in-
fusion of ET-1 markedly decreases renal blood ﬂow (RBF) and
glomerularﬁltration rate (GFR) due to a profound and sustained increase
in renal vascular resistance (Kohan et al, 2011). The sustained renal vaso-
constriction is often preceded by a transient vasodilatory response possi-
bly due to ETB receptor mediated release of nitric oxide (NO) (Abassi et
al., 2001; Kalani, 2008; Kon and Badr, 1991; Naicker and Bhoola, 2001;
Wilhelm et al., 1999).
Elevated levels of ET-1 are found in patients with DM, where it con-
tributes to the reduced insulin sensitivity and development of metabol-
ic syndrome. Enhanced ET-1 production by vascular endothelium exists
as an early phenomenon rather than a result of advanced stage of DM
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ECs exposed to increased levels of glucose enhanced the production of
ET-1. Similar results were reported by Park et al. (2000) in both retinal
capillary ECs. In streptozotocin diabetes models, we have showed that
kidney medullary endothelin converting enzyme-1 protein and gene
expressionwere gradually increased 7–14 days following the induction
of DM (Khamaisi et al., 2008). It is widely accepted that increased pro-
duction of ET-1 plays a mandatory role in the pathogenesis of endothe-
lial dysfunction and renal injury characterizing patients with DM
(Brownlee, 2005; Goligorsky et al., 2001; Kalani, 2008; Neuhofer and
Pittrow, 2006). Additionally, glucose, advanced glycated end products
and induction of plasminogen activator inhibitor-1, have the ability to
scavengeNO in the initiation phase of endothelial dysfunction, resulting
in decreased expression of endothelial nitric oxide synthase (eNOS) and
reduced generation of NO (Verbeke et al., 2000; Goligorsky et al., 2001).
Acute kidney injury (AKI) is a termdescribing decrease in renal func-
tion with rapid deterioration of glomerular ﬁltration rate (GFR), result-
ing in retention of urea, creatinine and other waste products (Schrier
et al, 2004; Lameire et al., 2005; Lameire and Vanholder, 2004; Van
Biesen et al., 2006). The ischemic renal damage is largely attributed to
oxidative stress, inﬂammation and endothelial dysfunction. The latter
is characterized by an imbalance between the release of ET-1 and NO
(Goligorsky, 2005; Lameire and Vanholder, 2004; Bonventre and Yang,
2011). It has been shown that ET-1 concentrations are increased during
the initial 24 h following reperfusion in experimental ischemic AKI
(iAKI) (Wilhelm et al., 1999). Additionally, it has been reported that pa-
tients with AKI have elevated plasma concentrations of ET-1 (Naicker
and Bhoola, 2001; Neuhofer and Pittrow, 2006; Wilhelm et al., 1999).
Diabetes has been recognized as a risk factor for the development of
AKI in a variety of clinical settings, such as radio-contrast nephropathy
or following cardiopulmonary bypass operations. The increased suscep-
tibility of the kidney to AKI has been previously reported in patients
with diabetes mellitus and experimental models of this disease
(Bellomo et al., 2004; Shi et al., 2007; Woodrow et al., 1994). However,
themechanisms underlying the enhanced vulnerability of the kidney to
ischemia in diabetes have not been clearly established.We assume that
DM could augment renal damage induced by ischemia-reperfusion in
part by aggravation of endothelial dysfunction. Therefore, in the present
study we investigated the contribution of ET-1 and NO systems to the
increased susceptibility of the diabetic kidney to ischemic insult, by
using selective blockers of ET-1 receptors, and NOS inhibitors.
Materials and methods
Studies were conducted on male Sprague Dawley rats, weighing
~300 g. All experiments were performed according to the guidelines
of the Committee for the Supervision of Animal Experiments, Technion,
IIT.
Animal model of diabetes
The animals were rendered diabetic by a single intraperitoneal in-
jection of Streptozotocin (STZ, 65 mg/kg body weight; obtained from
Sigma–Aldrich Co., USA) dissolved in sodium citrate buffer (pH 4.5). Di-
abetes was conﬁrmed 5 days later by blood glucose sampling from the
tail tip by glucometer (Ascensia Elite XL, Milano, Italy).
Ischemia reperfusion injury
Five days after STZ injection, the animalswere anesthetized by intra-
peritoneal injection of sodium pentobarbital (50 mg/kg body weight)
and placed on a thermoregulated table. Unilateral renal ischemia was
produced by clamping the left renal artery for 30 min. To minimize de-
hydration of the exposed tissues, the abdominal area was covered with
saline-soaked gauze. For reperfusion, the clampwas removed and blood
ﬂow to the kidney was reestablished with visual veriﬁcation of bloodsupply. Subsequently the abdomen was sutured, and the animals
were returned to their cages for 48 h.Clearance studies
Seven groups of rats were studied: 1) Control Rats, normoglycemic
(n=7); 2) Diabetic rats (n=8); 3) Diabetic rats±ETA receptor antago-
nist, pretreated with the selective ETA receptor antagonist ABT-627
(10 mg/kg P.O.) for 7 days immediately following STZ injection
(n=9); 4) Diabetic rats±ETB receptor antagonist, pretreated with the
selective ETB receptor antagonist A192621.1 (10 mg/kg/day P.O.) for
7 days immediately following STZ injection (n=7); 5) Diabetic rats±
L-NAME, pretreated with the nonspeciﬁc NOS inhibitor L-NAME
(15 mg/L in drinkingwater, Sigma–Aldrich) for 7 days immediately fol-
lowing STZ injection (n=9); 6) Diabetic rats±1400W, pretreated
with the iNOS inhibitor 1400W (3mg/kg S.C., Alexis Biochemicals)
for 3 days starting 2 h before ischemia (n=9); 7) Diabetic rats±
NPLA, pretreatedwith the nNOS speciﬁc inhibitorNG-propyl-L-arginine
NPLA (3 mg/kg I.V. boluses through the tail vein, Alexis Biochemicals)
for 3 days starting 2 h before ischemia (n=6).
On the day of the experiments, animals were anesthetized with
Inactin (100 mg/kg, i.p.) and prepared for clearance studies (Fuhr
et al., 1955). After tracheotomy, polyethylene tubes (PE50) were
inserted into the carotid artery and jugular vein for blood pressure
monitoring and infusion of solutions, respectively. For urine collec-
tion, catheters were inserted through a supravesical incision into
both the left ureter (PE10) and the bladder (PE50), to monitor the
ischemic kidney and the control kidney, respectively. A solution
of 2% inulin in 0.9% saline was continuously infused throughout
the experiment. Mean arterial pressure (MAP) was continuously
monitored with a pressure transducer (model 1050.1, UFI, Morro
Bay, CA) connected to the carotid artery. After a 60 min. equilibra-
tion period, urine was collected separately from each kidney in
timed periods and a reference blood sample was drawn between
every two urine collections.Chemical analyses
Urine volume was determined gravimetrically. Sodium concentra-
tions of in plasma and urine were determined by a ﬂame photometer
(model IL 943, Instrumentation Laboratories, Italy). Inulin concentra-
tions in plasma and urine were measured by colorimetric methods.
Glomerular ﬁltration rate (GFR) was equated with the clearance of in-
ulin (Cin=Uin*V/Pin).Western blot
Kidneys were sectioned and the medulla and cortex were separated
on ice. Tissues were homogenized within Ripa (Radio-Immunoprecipi-
tation Assay) buffer containing protease and phosphatase inhibitors.
100 μg of protein was treated with sample buffer then electrophoresed
on 7.5% polyacrylamide Tris-glycine gels and transferred electrophoret-
ically to a nitrocellulosemembrane. Themembranes were blocked in 5%
milk and incubated with 300-fold-dilutede eNOS, iNOS or nNOS poly-
clonal antibodies (Santa Cruz, sc-654, sc-651, and sc-648, respectively)
overnight at a 4 °C, followed by washing the membranes three times
with T-TBS. Then, the blots were incubated with 2000-fold-diluted
peroxidase-conjugated goat anti-rabbit IgG secondary antibody (Sigma
Chem1icals) for 60 min. Immunoreactive bands were visualized by En-
hanced chemiluminescence detection system (Amersham). The density
of autoradiographic signals were quantitated using Toolbar (Nonlinear
Dynamics Ltd.,Newcastleupon Tyne, UK). Quantitated bands were nor-
malized to β-actin densities.
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Hematoxylin and Eosin (H & E) staining was performed in parafﬁn
embedded longitudinal 5-μm kidney's sections. Morphological changes
were noted in the kidneys subjected to ischemic and non-ischemic kid-
neys, and determined by a semi-quantitative analysis using a 0–4 score.
The 4th grade reﬂecting en block infarction of the entire region exam-
ined, casts detected in all tubuli, extensive congestion and extravasation
of red cells into the parenchyma, and extensive polymorphonuclear in-
ﬁltration, respectively, as described by Kiris et al (2008).
Statistical analysis
Paired t-testwas applied for comparisons between the ischemic kid-
ney and the control kidney from the same experiment. One-way
ANOVA, followed with Dunnett's test as post-ANOVA evaluation, was
used for group comparisons (where the diabetic group serving as con-
trol group for the statistical tests). Data are expressed as mean±SEM.
P-value b0.05 was considered statistically signiﬁcant.
Results
Effects of ischemia-reperfusion injury on renal function in diabetic rats
Diabetic rats exhibited signiﬁcant weight loss and dramatic increase
in blood glucose levels (Table 1). Ischemia decreased GFR (Fig. 1A),
urine ﬂow rate (Table 1), and sodium excretion (UNaV) (Fig. 1B) in
both non-diabetic and diabetic rats. The decline in GFR, V, and UNaV
following ischemia was more severe in diabetic rats compared to non-
diabetic rats. These ﬁndings clearly demonstrate that the diabetic
kidney is more susceptible to ischemic injury than the non-diabetic
kidney.
Effects of ischemia-reperfusion injury on renal morphology in diabetic
rats
Ischemia-reperfusion injury in normoglycemic rats was associated
with necrosis and casts, mainly in the outer stripe of the renal outer
medulla, and this effect was more profound in diabetic rats. A broader
pattern of injury in the diabetic ischemic kidney was noted in theTable 1
Effects of the various treatments on % in B.W & K.W, blood glucose, mean arterial pressure
Effect of various treatments on B.W & K.W expressed as (% changed in B.W and K.W), blood g
test day. Urine ﬂow rate (V) from each kidney along the clearance experiments, N; Normal
(+) Pb0.05 , (++)Pb0.01, (+++) Pb0.0001, normal vs. ischemia in the same group; (#)
Experimental Group B.W K.W
% change from
baseline
Normoglycemia (n=7) +2.37±0.88 +18.8±3.8
Diabetes (n=8) -13.9±1.08⁎⁎⁎ +31.3±5.2
Diabetes+ETA antagonist (n=9) -11.33±1.15 +38.1±5.7
Diabetes+ETB antagonist (n=7) -16.7±1.46 +30.4±7.2
Diabetes+L-NAME (n=9) -15.96±1.2 +14.5±2.6⁎⁎
Diabetes 1400W (n=9) -9.97±0.86⁎ +29.3±7.0
Diabetes+NPLA (n=6) -7.04±1.12⁎⁎⁎ +24.5±5.5inner stripe of the outer medulla, including also congestion and in-
ﬂammation, with all pathological parameters higher than 2.5 in the
morphological score [0–4] (Fig. 2). It should be emphasized that dia-
betes alone had no histological effects on the non-ischemic kidney
(data not shown).Effects of ABT-627, a selective ETA antagonist, on renal function after ischemic
injury in diabetic rats
ABT-627decreased MAP in diabetic rats from 122.1±1.4 mmHg to
101.2±2.3 mmHg (Pb0.001), and decreased V and UNaV in the ische-
mic and normal kidney in diabetic rats. Blockade of ETA receptor did
not affect GFR of the normal kidney in diabetic rats. In contrast,
ABT-627 tended to increase GFR of the ischemic kidney by 2-fold in
diabetic animals (from 26.35±11.51 to 57.99±35.47 μl/min in dia-
betic non-ischemic and ischemic kidney, respectively, (P=NS))
(Fig. 1A and B).Effects of A192621.1, a selective ETB antagonist, on renal function after
ischemic injury in diabetic rats
A192621.1 aggravated the loss of body weight (B.W.) but signiﬁ-
cantly reduced blood glucose levels (Table 1). At the renal level, ETB an-
tagonist remarkably declined V in the ischemic and non-ischemic
kidney. ETB blockade did not have any impact on UNaV in the normal
kidney but decreased signiﬁcantly UNaV in the ischemic kidney of dia-
betic rats. Noteworthy, the drug caused a remarkable decrease in GFR
both in non-ischemic and ischemic diabetic kidneys (Fig. 1A and B).Effects of ET-1 receptor blockers on renal morphology after ischemic injury
in diabetic rats
ABT-627 decreased necrosis, casts and inﬂammation in the outer
stripe of the renal ischemic diabetic outer medulla. Likewise,
A192621.1 decreased necrosis and casts but increased congestion and
inﬂammation in the outer stripe of the renal ischemic diabetic outer
medulla (Fig. 2A). Selective antagonists of ET-1 receptors had no effect
on the injury in the inner stripe of the outer medulla, where the main
injury occurred (Fig. 2B).(MAP), and urinary ﬂow rate (V) of the experimental groups.
lucose levels 5 days after inducing hyperglycemia, mean arterial pressure (MAP) in the
Kidney I; Ischemic Kidney (⁎) Pb0.05, (⁎⁎) Pb0.01, (⁎⁎⁎) Pb0.0001 vs. nomoglycemic;
Pb0.05, (##) Pb0.01, (###) Pb0.0001 vs. untreated diabetes.
Blood Glucose
(mg %)
MAP (mmHg) V (ml.min)
112.28±4.67 132.1±4.2 N 7.22±1.24
I 5.5±1.53
503.1±14.92⁎⁎⁎ 122.1±1.4 N 19.6±1.62⁎⁎
I 1.48±0.41⁎⁎⁎
446.5±16.32⁎⁎⁎ 101.2±2.3⁎⁎⁎,### N 14.56±1.1
I 1.3±0.52⁎⁎⁎
409±42.49⁎⁎⁎,# 117.3±4.1⁎⁎ N 15.56±2.9⁎,#
I 0.29±0.09⁎⁎
458.92±16.9⁎⁎⁎ 148.8±6.4### N 11.35±1.2
I 2.58±0.59⁎⁎⁎
461±18.6⁎⁎⁎ 148.8±6.4### N 12.96±1.5
I 3.72±2.3⁎
395±20.4⁎⁎⁎,## 107±3.8⁎ N 24.49±7.2
I 11.64±5.1#
Fig. 1. Effects of selective ET-1 receptors antagonists on GFR in diabetic rats sub-
jected to ischemic renal injury. Effect of selective ETA antagonist (ABT-627) and selec-
tive ETB antagonist (A192621.1) on GFR of ischemic and non-ischemic kidneys in diabetic
rats (A). Urinary sodium excretion (B).
Fig. 2. Effects of selective ET-1 receptors antagonists on morphological changes in
the renal ischemic outer medulla. Effect of selective ETA antagonist (ABT-627) and
selective ETB antagonist (A192621.1) on morphological changes (necrosis, casts, con-
gestion and inﬂammation) in the renal ischemic outer medulla.
672 N. Abu-Saleh et al. / Life Sciences 91 (2012) 669–675Effect of various NOS inhibitors on renal function after ischemic injury in
diabetic rats
iNOS expression increased 6 h following ischemia by 2 fold in normo-
glycemic and diabetic renal cortex.While iNOS upregulation persisted in
normoglycemic kidneys after 18 h and 48 h following ischemic injury, it
decreased in the diabetic kidney. The enhanced expression of iNOS was
even more profound in the renal medulla, where it increased by 1.5
fold in diabetic non ischemic kidney, and 2 fold, and 3 fold in normogly-
cemic and diabetic kidney 6 h following ischemia. iNOS levels decreased
after 18 h of AKI induction in all groups.
Cortical eNOS decreased by ~30%, 32% and 63% in diabetic non is-
chemic, ischemic normoglycemic, and ischemic diabetic kidneys 48 h
after reperfusion, respectively. Similarly, diabetic medulla showed a
20% decrease in eNOS levels as compared to normoglycemic medulla
at the same time point. Ischemic injury decreased eNOS level in nor-
moglycemic and diabetic medulla by 66% and 54%, 6 h following is-
chemia, respectively. These decreases were even more profound
48 h after AKI, where eNOS levels declined by 70% in normoglycemic
ischemic medulla and by 84% in diabetic ischemic medulla. In sum-
mary, the ischemic diabetic medulla was most affected, where iNOS
increased in the early stages of AKI, and eNOS decreased through
48 h of AKI to 20% of the baseline levels.
Non-speciﬁc inhibition of NOS by L-NAME in diabetic rats signiﬁ-
cantly increased MAP and improved kidney swelling (as expressed by
kidney weight (K.W)). L-NAME caused a decline in V and UNaV in nor-
mal kidney but improved V in ischemic kidney as compared with
untreated diabetic rats. GFR signiﬁcantly decreased in normal diabetic
kidney after the administration of L-NAME. On the other hand, in theischemic kidney, L-NAME increased GFR by 3 fold. Although it did not
reach statistical signiﬁcance, GFR ratio, deﬁned as % change from non-
ischemic kidney, was attenuated from a decline of 97.66±1.14% in dia-
betic rats without treatment to 86.3±4.1% decline in L-NAME treated
rats (Fig. 3A and B).
Treatment with 1400 W, a speciﬁc inhibitor of iNOS, exerted a
beneﬁcial effect on V and UNaV in the ischemic kidney of the diabetic
rats. Moreover, 1400 W improved GFR in ischemic kidney by almost 4
fold. Actually, percent decline in GFR improved from 97.66±1.14% in
untreated diabetic rats to 87.8±3.96% in 1400 W treated animals
(Fig. 3A and B).
Treatment with NPLA, nNOS inhibitor, attenuated the reduction in
B.W, showed improvement in kidney weight and decreased blood
glucose levels in diabetic rats during the experiment duration
(Table 1). NPLA exerted a stimulatory effect on V and UNaV in non-
ischemic and ischemic kidneys of treated rats as compared with dia-
betic non-treated rats (Fig. 3B). NPLA enhanced GFR in ischemic kid-
ney by ~6 fold (Pb0.005). This beneﬁcial effect is demonstrated by a
59.4±19% reduction in GFR (in the ischemic kidney relative to the
normal kidney in rats treated with NPLA, compared with a GFR de-
cline of 97.66±1.14% in untreated diabetic rats (Fig. 3A).
Effects of NOS blockers on renal morphology after ischemic injury in dia-
betic rats
L-NAME decreased necrosis, and casts in both outer and inner
stripe of the renal ischemic diabetic outer medulla. In addition, it de-
creased congestion and inﬂammation only in the inner stripe of the
outer medulla. 1400 W and NPLA decreased necrosis and casts in
Fig. 3. Effects of selective and non-selective NOS inhibitors on GFR in diabetic rats
subjected to ischemic renal injury. Effect of nonspeciﬁc NOS inhibitor (L-NAME), iNOS
inhibitor (1400W) and nNOS inhibitor (NPLA) on GFR of ischemic and non-ischemic kid-
neys in diabetic rats (A). Urinary sodium excretion (B).
Fig. 4. Effects of selective and non-selective NOS inhibitors on morphological
changes in the renal ischemic outer medulla. Effect of nonspeciﬁc NOS inhibitor (L-
NAME), iNOS inhibitor (1400W) and nNOS inhibitor (NPLA) on morphological changes
(necrosis, casts, congestion and inﬂammation) in the renal ischemic outer medulla.
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ic outer medulla. Although all NOS inhibitors decreased cast and ne-
crosis in the outer medullary stripe of the ischemic kidney, the
effects of 1400 W did not reach statistical signiﬁcance (Fig. 4A and B).Discussion
The ﬁndings of our study provides new insights into the mecha-
nisms underlying the vulnerability of the diabetic kidney to ischemic
damage, speciﬁcally on the role of ET-1 and NO systems in the path-
ogenesis of renal dysfunction in diabetic rats with and without ische-
mia. These ﬁndings may prove relevant for development of novel
therapeutic approaches that rely on these mechanisms.
Reperfusion of the ischemic kidney may lead to massive cellular
damage apart from the injury caused directly due to the occlusion itself.
Previously, it has been shown that iAKI in rats increases ET-1 levels
(Naicker and Bhoola, 2001; Neuhofer and Pittrow, 2006), iNOS expres-
sion (Lameire and Vanholder, 2004), and decreases eNOS abundance in
the renal cortex and medulla. Therefore, it is reasonable to assume that
the diabetic kidney is more susceptible to ischemic reperfusion injury
than the non-diabetic kidney and imbalance between these NO and
ET-1 systems may contribute to this phenomenon. Based on this as-
sumption, we examined the effect of iAKI on renal function in diabetic
rats and assessed the alterations in the expression of the various NOS
isoforms and ET-1 system in the ischemic kidney as compared with
the relevant controls.Ourﬁndings demonstrate that ischemic injury in either normoglyce-
mic or diabetic rats induced necrosis and cast formation mainly in the
outer stripe of the outer medulla. However, ischemia in diabetic rats
caused a more excessive increase in necrosis and casts in both the
inner and outer stripe of the medulla, indicating that diabetic kidney
is more susceptible than normoglycemic to morphological changes
when subjected to AKI. Along these histological changes, ischemic kid-
ney in nomoglycemic rats exhibited a 60% and 38% decreases in GFR
and UNaV respectively as compared with basal values. These deleterious
renal hypoperfusion and impaired excretory function of AKI are compa-
rable to those reported by other groups who used a similarmodel of the
disease. For instance, Lin et al. (1988) showed that rats that were sub-
jected to 30 min of renal artery occlusion displayed after 5 days 50% re-
ductions in GFR, V and UNaV. Interestingly, when renal ischemia was
induced in diabetic animals it resulted in more profound declines in
GFR (by 98%) and inUNaV (by 87%), which were signiﬁcantly greater
than those obtained in ischemic normoglycemic rats. These ﬁndings
are in line with reports by other groups. For example, Melin et al.
(1997) showed that renal ischemia of 30 min in diabetic rats caused a
substantial decrease in the clearance of inulin (GFR) to ~20% of that
measured in ischemic normoglycemic animals. Similarly, Goor et al.
(1996) demonstrated that renal artery clamping for 60 min resulted in
amore severe acute renal damage in diabetic animals than that obtained
in ischemic non-diabetic group. Speciﬁcally, creatinine clearance values
in the diabetic ratswere half of thosemeasured in ischemic normoglyce-
mic rats. Additionally, Shi et al. (2007) showed that renal ischemia in di-
abetic db/dbmice results in impairment in renal reperfusion to both the
cortex and the medulla during the early post-ischemic period, and that
diabetic mice subjected to ischemic injury exhibit delayed recovery of
674 N. Abu-Saleh et al. / Life Sciences 91 (2012) 669–675renal regional blood ﬂow. Unfortunately, these authors did not examine
the mechanisms responsible for the exaggerated sensitivity of the dia-
betic kidney to ischemic damage and have not evaluated the effects of
potential therapeutic approaches.
In attempt to explain the severeworsening in renal function in ische-
mic diabetic kidney, we investigated the involvement of key regulators
of kidney function, speciﬁcallyET-1 and NO, after a renal ischemic insult
in diabetic rats.
Our data show that an ETA antagonist moderately improved GFR in
ischemic kidney without affecting GFR in non-ischemic kidney of dia-
betic rats. This suggests that ET-1, via ETA receptor,mediates renal vaso-
constriction and subsequently impairs GFR (Naicker and Bhoola, 2001).
Furthermore, ETA antagonism decreased necrosis and casts in the outer
stripe of the ischemicmedulla, an effect thatmay have beneﬁcial impact
on kidney function. Unexpectedly, ETA antagonist worsened UNaV in
both ischemic and non-ischemic kidneys. This effect is at odds with
the stimulatory effects of ETB on sodium excretion (Naicker and
Bhoola, 2001), but it may be a result of the hypotensive effects of ETA
antagonism. Alternatively, ABT-627 may bind non-selectively to ETB
during AKI, although we have no data to support this assumption. As
expected, the ETB antagonist decreased GFR, V and UNaV in non-
ischemic, and to a greater extent in ischemic kidneys of diabetic ani-
mals. These effects complywith the physiological roles of the ETB recep-
tor in the kidney, where it promotes natriuresis and diuresis via NO and
PGI2 production, which also known to induce vasodilation (Kohan et al,
2011; Naicker and Bhoola, 2001). In line these ﬁndings, Pfab et al.
(2006) reported that ETB deﬁciency in diabetic rats causes progressive
renal failure, severe hypertension, albuminuria, and a mild reduction
of creatinine clearance (Pfab et al., 2006).
Nonspeciﬁc inhibition of the three isoforms of NOS by L-NAME had a
mild beneﬁcial effect on GFR in the ischemic diabetic kidney, but not in
the non-ischemic one. Additionally, L-NAME improved urine ﬂow rate
in the ischemic kidney but worsened it in the non-ischemic kidney.
These effects may highlight the importance of the balance between
the three NOS isoforms in the regulation of renal hemodynamics and
excretory function. Accordingly, the deleterious effects of L-NAME on
kidney function in the non-ischemic diabetic kidney as compared
with its beneﬁcial effects on the ischemic diabetic kidney ﬁt our obser-
vation that renal iNOS is upregulated more intensively in the ischemic
diabetic kidney as compared to the non-ischemic one. These beneﬁcial
effects were associated with remarkable morphological changes,
where inhibition of NOS isoforms by L-NAME signiﬁcantly decreased
casts and necrosis in the outer and inner stripe of the ischemic medulla,
in combination with decline in congestion and inﬂammation in the
inner stripe. Although L-NAME inhibits all NOS isoforms, it is appealing
to assume that these encouraging effects of L-NAME are due to its ability
to inhibit iNOS, which is known to play critical role in inﬂammation and
oxidative stress.
NPLA, a speciﬁc inhibitor of nNOS, exerted positive effects on the
ischemic kidney's GFR, V and UNaV, whereas in non-ischemic kidney
it decreased GFR. In addition, NPLA derived morphological enhance-
ment by decreasing casts and necrosis in the outer stipe of the outer
ischemic medulla. Previous studies have demonstrated that inhibition
of nNOS enhances tubulo-glomerular feedback (TGF) activity. In-
creased sensitivity of the TGF system reduces GFR, urine ﬂow rate
and sodium excretion rate (Blantz et al., 2002). It should be empha-
sized that these ﬁndings are in line with the well-established concept
that nNOS plays a beneﬁcial role in maintaining renal hemodynamics
and kidney function under non-ischemic conditions (Ollerstam and
Persson, 2002; Blantz et al., 2002). However, our ﬁnding that NPLA
improves kidney function after ischemic insult in diabetic rats, sug-
gest that nNOS may play an adverse role in renal dysfunction under
this situation. Support for this notion comes from knock-out studies,
where it was reported that knockout of nNOS reduced tissue damage
in experimental models of stroke and cerebral ischemia (Vallance and
Leiper, 2002).As expected, 1400W, a speciﬁc iNOS inhibitor, produced beneﬁcial ef-
fects on the ischemic diabetic kidney's GFR. In addition, 1400W increased
UNaV and V, and attenuated the diuretic response characterizing hyper-
glycemia without affecting GFR in non-ischemic diabetic kidney. Thus,
iNOS inhibition partly restored the impaired renal function parameters
in the ischemic diabetic kidney. These encouraging ﬁndings probably
are derived from the fact that iNOS is associated with inﬂammation and
ROS production in the ischemic renal cells, and its inhibition ameliorates
these adverse responses.However, themild improvement in kidney func-
tion following iNOS inhibitor treatment, suggests that iNOS is only one
player amongmany that contribute to the impaired renal function follow-
ing ischemic insult. As evidenced, we have shown the involvement of an-
other deleterious factor, namely ET-1, in the pathogenesis of renal
damage under this condition.
Conclusion
In summary, our ﬁndings show that ischemia alone in normoglyce-
mic rats results in severe reduction in renal hemodynamic and excretory
function, as expressed by remarkable decreases in V, UNaV and GFR. In-
terestingly, when the same ischemic procedure was applied in diabetic
rats, the deleterious effects on renal function were greater than those
obtained in normoglycemic animals and the kidney exhibited poor re-
covery. The exaggerated vulnerability of the diabetic kidney to the ische-
mic insult could be attributed to activation of the endothelin system.
Moreover, upregulation of the harmful NOS isoform, iNOS, in parallel
to down regulation of the beneﬁcial isoform eNOS, may contribute to
this phenomenon. Yet, additional studies are required to explore this
issue.
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